drugset / Trial / NCT03340506
Dabrafenib and/or Trametinib Rollover Study
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the requirements for the primary objective, and who are judged by the investigator as benefiting from continued treatment in the parent study as judged by the Investigator at the completion of the parent study.
Timeline
- Start
- 2018-01-26
- Primary completion
- 2032-12-28
- Completion
- 2032-12-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dabrafenib | Small molecule | 50 mg | — |
| Subject | Dabrafenib | Small molecule | 75 mg | — |
| Subject | Trametinib | Small molecule | 0.5 mg | — |
| Subject | Trametinib | Small molecule | 2 mg | — |